KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Assets Average: 2009-2025

Historic Assets Average for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to $1.3 billion.

  • Novavax's Assets Average fell 28.74% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 28.74%. This contributed to the annual value of $1.7 billion for FY2024, which is 17.21% down from last year.
  • As of Q3 2025, Novavax's Assets Average stood at $1.3 billion, which was down 4.30% from $1.3 billion recorded in Q2 2025.
  • Novavax's Assets Average's 5-year high stood at $2.7 billion during Q2 2022, with a 5-year trough of $1.3 billion in Q3 2025.
  • Its 3-year average for Assets Average is $1.6 billion, with a median of $1.6 billion in 2023.
  • In the last 5 years, Novavax's Assets Average surged by 736.45% in 2021 and then plummeted by 40.86% in 2023.
  • Quarterly analysis of 5 years shows Novavax's Assets Average stood at $2.6 billion in 2021, then decreased by 11.99% to $2.3 billion in 2022, then fell by 23.67% to $1.7 billion in 2023, then decreased by 5.26% to $1.6 billion in 2024, then fell by 28.74% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.4 billion during Q1 2025.